StockData
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF

Renalytix plc

Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)

Close on Oct 19, 2026

Market cap
$375.75M
P/E (TTM)
–
Dividend yield
–

Renalytix plc income statement

Ratios

Latest available, balances at Sep 30, 2024

Profitability, TTM

Gross margin
12.7%
Operating margin
-1054.9%
Net margin
-1191.8%
Return on equity, FY2024
7543.6%

Financial strength

Current ratio
0.24
Debt to equity
–
Debt to assets
–
Cash to current liabilities
7.6%

Valuation

P/E ratio
–
Price to sales
159.76
Price to book
–
Dividend yield
–